01 8Lotriga
02 3Lovaza
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 292
2018 Revenue in Millions : 292
Growth (%) : 0
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 299
2019 Revenue in Millions : 298
Growth (%) : 0
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 268
2020 Revenue in Millions : 287
Growth (%) : 1
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 163
2021 Revenue in Millions : 268
Growth (%) : -39
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 23
2022 Revenue in Millions : 61
Growth (%) : -57
Omega-3 Polyunsaturated Fatty Acids
Main Therapeutic Indication : Cardiovascular
Currency : USD
2015 Revenue in Millions : 341
2014 Revenue in Millions : 132
Growth (%) : -61%
Omega-3 Polyunsaturated Fatty Acids
Main Therapeutic Indication : Cardiovascular
Currency : USD
2014 Revenue in Millions : -58.90%
2013 Revenue in Millions :
Growth (%) :
Omega-3 Polyunsaturated Fatty Acids
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 53
2015 Revenue in Millions : 115
Growth (%) : -54
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 239
2015 Revenue in Millions : 189
Growth (%) : 27
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 300
2016 Revenue in Millions : 255
Growth (%) : 17
LOOKING FOR A SUPPLIER?